In 2013, Emory created DRIVE, a not-for-profit drug development group with the primary purpose of fighting infectious disease. DRIVE focuses on developing therapeutic agents for unmet medical needs and emerging diseases. Fitting within its mission, DRIVE is developing EIDD-1931/2801 to treat emerging and biodefense viruses, including chikungunya, influenza, Venezuelan equine encephalitis virus (“VEEV”), Ebola, and Zika. EIDD-1931, a ribonucleoside analog, is readily transported into cells and easy to synthesize.